Table 3.
Factors associated with the occurrence of adverse reactions among healthcare professionals in Addis Ababa, Ethiopia.
| Variables | COVID-19 adverse reaction | ||||
|---|---|---|---|---|---|
| Yes | No | COR (CI) | AOR (CI) | p value | |
| Gender | |||||
| Men | 69 (44.8) | 85 (55.2) | 1 | 1 | 0.01* |
| Women | 73 (59.3) | 50 (40.7) | 1.79 (1.13–2.906) | 1.50 (1.08–2.75) | |
| Age category | |||||
| <30 | 95 (55.2) | 77 (44.8) | 1.23 (0.17–8.96) | 0.88 (0.10–7.31) | 0.9 |
| 30–50 | 45 (44.6) | 56 (55.4) | 0.80 (0.10–5.93) | 0.61 (0.07–5.28) | 0.66 |
| >50 | 2 (50) | 2 (50) | 1 | 1 | |
| Suffering chronic diseases | |||||
| Yes | 4 (36.4) | 7 (63.6) | 0.53 (0.15–1.85) | 0.63 (0.12–3.25) | 0.58 |
| No | 138 (51.9) | 128 (48.1) | 1 | 1 | |
| COVID-19 vaccine types | |||||
| AstraZeneca (reference is No) | 108 (53.5) | 94 (46.5) | 1.38 (0.81–2.36) | 1.12 (0.75–2.25) | 0.13 |
| Johnson (reference is No) | 23 (53.5) | 20 (46.5) | 0.90 (0.46–1.72) | 0.65 (0.35–1.46) | 0.22 |
| Sinopharm (reference is No) | 0 | 11 (100) | 0.05 (0.01–0.23) | 0.03 (0.01–0.18) | 0.38 |
| Pfizer (reference is No) | 21 (67.7) | 10 (32.3) | 2.16 (0.98–4.79) | 0.88 (0.75–4.23) | 0.11 |
| COVID-19 vaccine received | |||||
| One time | 17 (35.4) | 31 (64.6) | 0.34 (0.12–0.97) | 0.24 (0.04–1.30) | 0.09 |
| Two times | 112 (53.8) | 96 (46.2) | 0.71 (0.28–1.80) | 0.73 (0.20–2.61) | 0.63 |
| More than two times | 13 (61.9) | 8 (38.1) | 1 | 1 | |
| Allergy to foods or medicines | |||||
| Yes | 19 (67.9) | 9 (32.1) | 2.16 (0.94–4.96) | 2.56 (1.86–7.59) | 0.04* |
| No | 123 (49.4) | 126 (50.6) | 1 | 1 | |
| Substance use | |||||
| Yes | 2 (40) | 3 (60) | 1.43 (0.23–8.73) | 0.98 (0.10–8.94) | 0.99 |
| No | 139 (51.1) | 133 (48.9) | 1 | 1 | |
| Recommend for others | |||||
| Yes | 122 (49.8) | 123 (50.2) | 0.59 (0.28–1.27) | 0.62 (0.27–1.42) | 0.26 |
| No | 20 (62.5) | 12 (37.5) | 1 | 1 | |
*
Indicate significantly associated variables.